Articles related to CLINICAL TRIALS

A recent phase 3 trial has shown that the combination of nivolumab and gemcitabine–cisplatin significantly improves survival rates in patients with previously untreated advanced urothelial carcinoma. This combination therapy resulted in a median survival of 21.7 months compared to 18.9 months with gemcitabine–cisplatin alone.

The EV-302/KEYNOTE-A39 trial has demonstrated a significant improvement in survival outcomes for patients with advanced bladder cancer, with the combination of enfortumab vedotin and pembrolizumab nearly doubling the median progression-free survival and overall survival compared to chemotherapy.

The phase 3 EXTENTORCH trial has demonstrated the potential of toripalimab plus chemotherapy as a new standard first-line therapy for ES-SCLC, with a median progression-free survival of 5.8 months.

The recent phase 3 trial has demonstrated the potential of amivantamab as a first-line treatment option for patients with advanced NSCLC with EGFR exon 20 insertions. The combination of amivantamab and chemotherapy significantly improved progression-free survival compared to chemotherapy alone.

The study underscores the potential of perioperative durvalumab in combination with neoadjuvant chemotherapy to significantly improve event-free survival and pathological complete response in patients with resectable NSCLC.

The recent study from CTAD 2023 has demonstrated the potential of p-tau217 as a promising biomarker for preclinical Alzheimer’s disease. This finding could significantly enhance our ability to detect Alzheimer’s at its earliest stages and initiate timely interventions.